Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 21212345...102030...Last »

IBM: Your Computer Can Help Scientists Study Connection Between Body Bacteria and Autoimmune Diseases

The general public’s help is being enlisted in what is believed to be the largest study of the human microbiome – the bacteria that live in and on the human body – and are believed to affect health.

Read More »

Global health price tag could be $371 billion a year by 2030, WHO says

Meeting life-saving global health targets by 2030 could require investments by donors and national governments of up to $58 per person per year, or $371 billion annually, the World Health Organization (WHO) said.

Read More »

BioPharm Executive: Let’s Get Rid of Clinical Trials

We’re living in volatile times. If I were to put a positive spin on that, I’d say that we’re living in times where a lot of accepted ways of doing things are being questioned. And those questions can be healthy. Take the FDA, for example. Pretty much every new president pays at least some lip service to the idea of speeding up drug approvals, cutting red tape, and helping the life sciences become more innovative. But President Trump apparently seriously considered appointing Jim O’Neill or Balaji Srinivasan as FDA Commissioner. Both O’Neill and Srinivasan are associates of Silicon Valley libertarian/iconoclast Peter Thiel, and have argued that drugs should be approved on the basis of safety alone, with the “market” deciding on whether they’re effective. (Healthcare is hardly a market in the normal sense of the term, hence the quotes.) O’Neill in particular would have done away with most clinical trials altogether.

Read More »

Sanofi Delivers Robust Q1 2017 Financial Results

Sanofi’s net sales for first-quarter 2017 amounted to €8.65 billion, up 11.1% on a reported basis and 8.6% at CER, reflecting the acquisition of Boehringer Ingelheim’s CHC business and full consolidation of Sanofi’s European vaccine operations. At constant structure and CER, net sales for the 2017 first quarter were up 3.5% year over year.

Read More »

On your bike: Cycling to work linked with large health benefits

People who cycle to work have a substantially lower risk of developing cancer or heart disease or dying prematurely, and governments should do all they can to encourage more active commuting, scientists said.

Read More »

South Korea culls 50,000 farm birds as 2 new bird flu cases confirmed

South Korea has culled some 50,000 farm birds as two cases of bird flu were confirmed on Wednesday, bringing the country’s cull this winter to nearly 35 million – more than a fifth of all South Korean poultry – since a first bird flu case was found late last year. The Ministry of Agriculture, Food […]

Read More »

House panels to launch fight in Congress over Obamacare replacement

A potentially lengthy U.S. legislative fight over replacement of the Obamacare health law got underway as two House of Representatives committees begin negotiating over changes to a Republican plan backed by President Donald Trump.

Read More »

Kaiser Permanente Study Finds Testosterone Replacement Therapy Reduces Cardiovascular Risk Among Men with Androgen Deficiency

Men who used testosterone replacement therapy to treat symptoms of androgen deficiency had a 33 percent lower risk of cardiovascular events such as heart attacks and stroke compared to those who did not receive any hormone therapy. The findings from the Kaiser Permanente study were published in JAMA Internal Medicine.

Read More »

U.S. top court rejects patent licensing appeal

The U.S. Supreme Court turned away an appeal of a Maryland state court jury verdict ordering Boston Scientific Corp. to pay $308 million to a patent licensor.

Read More »

Data on Trevena’s opioid painkiller irks investors

Only some doses of Trevena’s experimental opioid painkiller were found as effective as morphine in two late-stage studies, though the drug met its main study goals.

Read More »

FDA rejects Amphastar’s nasal opioid overdose treatment

Amphastar Pharmaceuticals Inc. said the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioid-overdose treatment, naloxone.

Read More »

This Tiny Biotech Grew 412% in 2016. A Look at Whether It Can Continue in 2017

Corbus Pharmaceuticals had a terrific 2016, with stock climbing 412 percent. Jim Crumly, writing for The Motley Fool, takes a look at the company and whether it can continue that trend for 2017.

Read More »

Sarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for $125 Million

Cambridge, Mass.-based Sarepta Therapeutics won a Rare Pediatric Disease Priority Review Voucher from the U.S. Food and Drug Administration when Exondys 51 was approved for Duchenne muscular dystrophy. The company announced that it had auctioned off its voucher for $125 million.

Read More »

‘Fasting-mimicking’ diet said to reduce risk factors for aging

Following a diet that mimics fasting may reduce risk factors for disease in generally healthy people, according to a small study.

Read More »

Interest in Nordic Nanovector’s NHL treatment

Norwegian biotech newcomer Nordic Nanovector, which seeks ways to treat blood-related cancers, says other companies are showing interest in buying the firm.

Read More »

Here’s Where Jobs in Shrinking Life Sciences Marketing Departments Are Headed

SCORR Marketing published the results of our third annual Health Sciences Marketing Trends Survey Report. While the report covers a broad range of information on marketing trends in our industry, one of the more notable findings is the shrinking size of marketing teams.

Read More »

Meet the Professor Who Was the First to Question Theranos’ Research

Investigative reports by the Wall Street Journal are largely credited with the downfall of would-be-biotech-disruptor Theranos, but there were members of the scientific community who were also raising concerns about the ultra-secretive company.

Read More »

Takeda Splits Off Its Consumer Healthcare Biz

Takeda Pharmaceutical has entered into an agreement to transfer its Japan Consumer Healthcare Business Unit to Takeda Consumer Healthcare.

Read More »

This Drug Could Rattle Biogen and Be the Next Billion-Dollar Blockbuster for Celgene

Celgene Corporation’s positive results for its Phase III SUNBEAM trial of ozanimod for relapsing multiple sclerosis not only is very good news for Celgene; it is potentially devastating news for Cambridge, Mass.-based Biogen.

Read More »

Phase II Study Supports Potential for Genentech’s Tecentriq Plus Avastin for People With Locally Advanced or Metastatic Renal Cell Carcinoma

Proof-of-concept study in first-line mRCC (a type of kidney cancer) shows that Tecentriq and Avastin can be combined with a manageable safety profile.

Read More »

Page 1 of 21212345...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!

Subscribe

Ad Right Bottom

Main Navigation